 Pliant Therapeutics

Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced three presentations at the upcoming 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place November 1 - 5, 2023 at the San Diego Convention Center in San Diego, California.

Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer

Interim results from INTEGRIS-PSC to be featured in an oral presentation on Monday, November 13 Interim results from INTEGRIS-PSC to be featured in an oral presentation on Monday, November 13

Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Ms. S. Mishima Gerhart as Chief Regulatory Officer. Ms. Gerhart will lead the Company's regulatory and quality strategies and activities.

Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer

Shares of Pliant Therapeutics, Inc. PLRX gained 14.3% on Sep 26 after the company announced that its mid-stage study on lead pipeline candidate bexotegrast was successful.

Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study

Pliant Therapeutics, Inc. (PLRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Pliant Therapeutics, Inc. (PLRX) Soars 14.3%: Is Further Upside Left in the Stock?

Pliant Therapeutics' bexotegrast shows multi-indicational promise, notably in primary sclerosing cholangitis, diversifying its asset utility beyond idiopathic pulmonary fibrosis. Financially, Pliant sustains a strong liquidity position with a 60-month cash runway but rising R&D and operational expenses warrant scrutiny. Investment Recommendation: Maintain a "Buy" stance on PLRX stock due to robust drug efficacy and financials, but exercise caution around upcoming clinical milestones and operational costs.

Pliant Therapeutics' Multi-Pronged Fibrosis Play

Pliant Therapeutics is a clinical-stage biotech. The company said it has enough cash to fund operations through the second half of 2026.

Why Shares of Pliant Therapeutics Are Rising Tuesday

Pliant Therapeutics Inc. shares PLRX, -2.86% gained 23% premarket on Tuesday after the company released results from a trial of bexotegrast, a treatment for a chronic liver disease. The trial met its primary and secondary goals, and bexotegrast was well tolerated over a 12-week treatment period in patients with primary sclerosing cholangitis (PSC) and suspected liver fibrosis, the company said in a release.

Pliant Therapeutics shares surge as liver-disease treatment shows promise in clinical trial

Bexotegrast (PLN-74809) was well tolerated over 12 weeks of treatment  with few discontinuations and no drug-related severe or serious adverse events

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced it will host a conference call and webcast on Tuesday, September 26, 2023 at 8:00 a.m. ET | 5:00 a.m. PT to discuss the interim results from the INTEGRIS-PSC Phase 2a trial. Members of Pliant's management will be joined by Gideon Hirschfield, FRCP, Ph.D., Lily and Terry Horner Chair in Autoimmune Liver Disease at the University of Toronto and a principal investigator in the INTEGRIS-PSC trial.

Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis

SOUTH SAN FRANCISCO, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the appointment of Ms. Minnie Kuo as Chief Development Officer. Ms. Kuo will oversee all aspects of the Company's nonclinical and clinical development activities.

Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced presentations made at the European Respiratory Society (ERS) International Congress 2023 taking place from September 9, 2023 to September 13, 2023.

Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced three upcoming presentations at the European Respiratory Society (ERS) International Congress 2023. The congress will take place in Milan, Italy from September 9, 2023 to September 13, 2023.

Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023

Pliant Therapeutics is a biotech company focused on developing therapies for fibrotic diseases. The company's financials show an increase in R&D and administrative expenses, as well as a net loss, but it has a strong liquidity position. Pliant's pipeline includes two clinical-stage programs targeting fibrosis pathways, with promising early results for their lead program, bexotegrast.

Pliant Therapeutics: Promising Phase 2a Bexotegrast Data Unveiled

Pliant Therapeutics, Inc. (PLRX) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $0.82 per share a year ago.

Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Misses Revenue Estimates

Initiation of Phase 2b BEACON-IPF trial of bexotegrast in patients with IPF INTEGRIS-PSC Phase 2a 12-week data of bexotegrast in patients with PSC expected in the third quarter of 2023 Initiation of Phase 1 trial of PLN-101095 in patients with solid tumors resistant to checkpoint inhibitors SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported second quarter 2023 financial results.

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the initiation of BEACON-IPF, a Phase 2b clinical trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF).

Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis

Presentations highlight preclinical and clinical advancements of bexotegrast program in primary sclerosing cholangitis Presentations highlight preclinical and clinical advancements of bexotegrast program in primary sclerosing cholangitis

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™

Undervalued: the stock is currently in the oversold territory after some investors over-reacted and sold after the Phase 2 BEXO trial, we like the FVC slow down and clean safety data. Promising Upcoming Trials: The mid-2023 Phase 2b BEACON-IPF trial could act as a significant positive catalyst for the stock, potentially meeting the FDA's criteria for a pivotal registration trial.

Pliant Therapeutics: Trading In Oversold Territory, Buying The Dip

Pliant Therapeutics, Inc. (PLRX) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.78 per share a year ago.

Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Misses Revenue Estimates

Positive long-term data from INTEGRIS-IPF 320 mg dose group at 24-weeks demonstrated bexotegrast was well tolerated with durable improvement shown across multiple measures

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

Bexotegrast was well tolerated up to 40 weeks of treatment  with no drug-related serious adverse events Combination of bexotegrast with standard of care reduced FVC decline by 80%  relative to standard of care alone at Week 24 89% of bexotegrast-treated patients with an increase in FVC from baseline  at Week 12 maintained an increase at Week 24 Stabilization of fibrosis as measured by QLF imaging was observed in the bexotegrast group  while the placebo group showed progression of fibrosis at Weeks 12 and 24 A reduction in patient-reported cough severity was reported in the bexotegrast group  in contrast to worsening in the placebo group BEACON-IPF Phase 2b trial to be initiated in mid-2023 Company to host webcast and conference call tomorrow, Monday, May 1 st at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif.

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures

Pliant Therapeutics: A Breath Of Fresh Air For A Multibillion Dollar IPF Market

SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., Pliant's President and Chief Executive Officer and Éric Lefebvre, M.D., Pliant's Chief Medical Officer, will participate in a fireside chat as part of the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19, 2023, at 3:45 p.m. Eastern Time.

Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference

Agios Pharmaceuticals

Amylyx Pharmaceuticals

Xencor

Harmony Biosciences Holdings

Kymera Therapeutics

Morphic Holding Inc

Generally speaking, biotech stocks to buy offer investors an excellent opportunity for significant upside success. According to Grand View Research, the global market size for the industry reached $1.02 trillion in 2021.

News for Pliant Therapeutics Stock (PLRX)